ETH-155008

DRUG2 trials

Sponsors

Shengke Pharmaceuticals Pty Ltd, Shengke Pharmaceuticals (Jiangsu) Limited, China

Conditions

AML, Adult RecurrentLeukemiaNHLNHL, Adult

Phase 1

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

TerminatedNCT04840784

Shengke Pharmaceuticals Pty LtdLeukemia, NHL

Start: 2021-06-29End: 2023-05-02Updated: 2023-10-11

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

RecruitingNCT05758610

Shengke Pharmaceuticals (Jiangsu) Limited, ChinaAML, Adult Recurrent, NHL, Adult

Start: 2022-11-04End: 2026-06-30Target: 60Updated: 2024-05-08